A COMPARISON BETWEEN GUIDELINES ON PRECLINICAL SAFETY EVALUATION OF MEDICINAL PRODUCTS OF THE EUROPEAN-COMMUNITY, THE NORDIC COUNTRIES, AND JAPAN

被引：0

|

作者：

GRIFFIN, JP

机构：

来源：

ATLA-ALTERNATIVES TO LABORATORY ANIMALS | 1985年 / 13卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

收藏

页码：53 / 63

页数：11

相关论文

共 40 条

[1] THE HISTORICAL RELATIONS BETWEEN THE NORDIC COUNTRIES AND THE EUROPEAN-COMMUNITY
SODERSTEN, B
[J]. WORLD ECONOMY, 1994, 17 (05): : 643 - 649
[2] THE APPROVAL OF MEDICINAL PRODUCTS IN THE EUROPEAN-COMMUNITY
SAUER, F
[J]. BIOFUTUR, 1989, (84) : 43 - 46
[3] TRADE BETWEEN JAPAN AND THE EUROPEAN-COMMUNITY
不详
[J]. EAST, 1981, 17 (9-10): : 30 - 31
[4] EUROPEAN-COMMUNITY HARMONIZATION OF THE LICENSING AND MANUFACTURING OF MEDICINAL PRODUCTS
FRIEDEL, E
FREUNDLICH, M
[J]. FOOD AND DRUG LAW JOURNAL, 1994, 49 (01): : 141 - 170
[5] ASPECTS OF EUROPEAN-INTEGRATION - A VIEW OF THE EUROPEAN-COMMUNITY AND THE NORDIC COUNTRIES - ALMDAL,P
THOMAS, AH
[J]. JOURNAL OF COMMON MARKET STUDIES, 1987, 25 (04): : 376 - 376
[6] COMPARISON OF ECONOMIC EVALUATION GUIDELINES BETWEEN JAPAN AND OTHER COUNTRIES
Millier, A.
Cheng, X.
Onishi, Y.
AballeaAballea, S.
Toumi, M.
Doley, J.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A832 - A833
[7] AGROINDUSTRIAL COOPERATION BETWEEN THE EUROPEAN-COMMUNITY AND THE ACP COUNTRIES
EUSSNER, A
[J]. JOURNAL OF COMMON MARKET STUDIES, 1986, 25 (01): : 51 - 73
[8] COMPARISON OF ECONOMIC EVALUATION GUIDELINES BETWEEN JAPAN AND OTHER ASIAN COUNTRIES
Millier, A.
Aballea, S.
Toumi, M.
Onishi, Y.
Ikeda, S.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A798 - A798
[9] A REVIEW OF DOCUMENTATION REQUIREMENTS FOR PRECLINICAL SECTIONS, FOR MARKETING SUBMISSIONS IN THE EUROPEAN-COMMUNITY, JAPAN AND THE USA
MARR, AP
SCALES, MDC
[J]. ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS, 1993, 12 (04): : 253 - 262
[10] COMPARISON BETWEEN GUIDELINES ON STABILITY-TESTS FOR ACTIVE SUBSTANCES AND FINISHED PRODUCTS ISSUED BY THE EUROPEAN-COMMUNITY AND THE UNITED-STATES-OF-AMERICA
VANDENAKKER, CR
[J]. PHARMAZEUTISCHE INDUSTRIE, 1991, 53 (05): : 483 - 489

← 1 2 3 4 →